Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Aichi Prefecture currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is distributed across 2 distinct examiners and 2 distinct art units, indicating a diverse spread of examination for a portfolio of this size. The involvement of multiple art units suggests that the entity's intellectual property covers different technical niches within the pharmaceutical sector.
STAVROU, CONSTANTINA E is identified as the busiest examiner for the company, currently overseeing 1 pending office action. This single action represents 1 of the 2 pending office actions for the portfolio. The use of 2 distinct art units suggests that the entity's intellectual property covers multiple specialized sub-sectors. Practitioners should note that with 2 distinct art units involved, the prosecution strategy must account for the specific guidelines and tendencies of different technical groups within the patent office to resolve the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STAVROU, CONSTANTINA E | 1 | 43.7% | +36.9% |
| HAMMELL, NEIL P | 1 | 34.6% | +43.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800718 | Medicine Containing USAG-1-Targeting RNA Molecule for Tooth Regeneration Therapy | HAMMELL, NEIL P | 73d overdue |
| 18571394 | CHIMERIC CYTOKINE RECEPTOR | STAVROU, CONSTANTINA E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17800718 | Medicine Containing USAG-1-Targeting RNA Molecule for Tooth Regeneration Therapy | HAMMELL, NEIL P | 73d overdue |
| 18571394 | CHIMERIC CYTOKINE RECEPTOR | STAVROU, CONSTANTINA E | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571394 | CHIMERIC CYTOKINE RECEPTOR | STAVROU, CONSTANTINA E | 1632 | §102§103§112 | Non-Final OA | — | Pending | Dec 18, 2023 |
| 17800718 | Medicine Containing USAG-1-Targeting RNA Molecule for Tooth Regeneration Therapy | HAMMELL, NEIL P | 1681 | §103§112 | Final Rejection | 73d overdue | Pending | Aug 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial